Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153693 | 0.85 | — | — | |
| SCHEMBL6757053 | 0.82 | — | — | |
| Benzene SCHEMBL27805857 | 0.79 | FFAR3 (0.38) | FFAR3NPSR1 | |
| SCHEMBL5090339 | 0.76 | PKM (0.37) | FFAR3 | |
| Bicarbonate SCHEMBL2900014 | 0.75 | — | — | |
| SCHEMBL3875210 | 0.74 | FFAR3 (0.48) | FFAR3APLNRMAPK1TP53NFKB1 | |
| SCHEMBL11399902 | 0.74 | FFAR3 (0.41) | FFAR3APLNRMAPK1TP53NFKB1 | |
| SCHEMBL4867997 | 0.74 | FFAR3 (0.82) | FFAR3APLNRMAPK1TP53NFKB1 | |
| SCHEMBL20299287 | 0.74 | FFAR3 (0.42) | FFAR3APLNR | |
| SCHEMBL321733 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313980-B1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC (CA) | 2026-04-22 | — | — | EP | disclosed |
| EP-4685147-A2 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | Fedora Pharmaceuticals Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| US-12528804-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| CN-118892553-A | Esatitecan analogue, ligand-drug conjugate thereof and application thereof | 浙江大学 | 2024-11-05 | — | — | CN | disclosed |
| EP-4313980-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | Fedora Pharmaceuticals Inc. (CA) | 2024-02-07 | — | — | EP | disclosed |
| CN-117500802-A | LACTIVICIN compounds, their preparation and their use as antibacterial agents | 费多拉制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-20220324858-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2022-10-13 | — | — | US | disclosed |
| WO-2022208356-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528804-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | LCT, LPO, CLSPN | FFAR3 957/4885APLNR 2863/4885MAPK1 2484/4885 |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | LCT, VIP, LPO | FFAR3 4701/4885APLNR 3906/4885MAPK1 1833/4885 |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | LCT, VIP, LPO | FFAR3 4699/4885APLNR 3851/4885MAPK1 1872/4885 |
| US-20220324858-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | LCT, VIP, LPO | FFAR3 4699/4885APLNR 3851/4885MAPK1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.